Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
IPO Year:
Exchange: NASDAQ
Website: avadel.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/12/2024 | $27.00 | Buy | Rodman & Renshaw |
3/5/2024 | $27.00 → $29.00 | Outperform | Oppenheimer |
3/5/2024 | $21.00 → $25.00 | Buy | H.C. Wainwright |
3/5/2024 | $20.00 → $22.00 | Buy | Needham |
2/6/2024 | $21.00 | Buy | UBS |
11/30/2022 | $6.50 → $11.00 | Hold → Buy | Jefferies |
8/10/2022 | $6.00 → $8.00 | Buy → Hold | Jefferies |
7/28/2022 | $15.50 → $12.00 | Buy | Craig Hallum |
5/26/2022 | $9.00 → $2.00 | Buy → Hold | Stifel |
1/11/2022 | $16.00 → $15.00 | Buy | Needham |
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens – – 91% reported being better able to sleep through the night after switching to LUMRYZ – – 93% of those who switched to LUMRYZ would recommend it to family or friends living with narcolepsy – DUBLIN, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of final data from the RESTORE open-label/switch study, demonstrating that people with narcolepsy prefer once-at-bedtime LUMRYZ versus a twice-nightly immediate-release
DUBLIN, Ireland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4 at 3:45 p.m. ET.Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Friday, September 6 at 10:00 a.m. ET.H.C. Wainwright 25th Annual Global Investment Conference: Fireside chat on Wednesday, September 11 at 11:30 a.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avad
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of results of a post-hoc analysis from the completed pivotal Phase 3 REST-ON clinical trial demonstrating greater weight loss in patients who received LUMRYZ compared with placebo. The paper, titled "Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial," was published online in Clinical Therapeutics. "Obesity is a struggle for
-- Generated $41.5 million in net revenue from sales of LUMRYZ™ -- -- More than 1,900 patients on LUMRYZ as of June 30th -- -- First patient dosed in Phase 3 trial evaluating LUMRYZ in idiopathic hypersomnia -- -- FDA target action date of September 7, 2024 for sNDA for LUMRYZ in pediatric narcolepsy -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the quarter ended June 30, 2024.
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are advised
DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the first patient has been dosed in REVITALYZ, a Phase 3 study evaluating LUMRYZ as a potential treatment for idiopathic hypersomnia (IH). "IH is a debilitating sleep disorder characterized by profound sleep inertia, or difficulty waking up and persistent profound daytime sleepiness. Awareness and diagnosis of IH has increased markedly over the last several years. However, IH patients are severely limited in effective treatment options, representing a large unmet need," said Richard K. Bogan, MD, FCCP, FA
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit
DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET. A live webcast of these events, as well as archived recordings, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following each conference. About Avadel Pharmaceuticals plc
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston. Approved by the U.S. Food and Drug Administration (FD
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to our board of directors," said Geoffrey M. Glass, Avadel Chairman of the Board. "Dr. Amin's extensive experience in identifying, developing, and commercializing new medicines for d
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
ARS - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
DEFA14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
DEF 14A - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care –DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.
HC Wainwright & Co. analyst Oren Livnat maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price target from $25 to $27.
Craig-Hallum analyst Chase Knickerbocker maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price target from $22 to $23.
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
Cash, cash equivalents and marketable securities were $88.8 million as of March 31, 2024.
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.21) by 42.86 percent. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.
Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume AKBA PUT SWEEP BEARISH 04/19/24 $2.00 $31.2K 6.5K 4.4K BMY CALL TRADE NEUTRAL 06/21/24 $60.00 $26.0K
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
3 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are advised
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and anno
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963 (International) and use the conference ID 2270373. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel
DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023. Avadel plans to issue its Annual Report on Form 10-K for the year ended December 31, 2023, on Thursday, February 29. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the web
DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here an
DUBLIN, Ireland, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 9, 2023, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2023. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are ad
-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy – -- FDA awarded LUMRYZ Orphan Drug Exclusivity through May 1, 2030 -- -- LUMRYZ product availability on track for early June; robust market research and physician feedback supports potential of LUMRYZ to capture a meaningful share of the $3 billion plus once-nightly oxybate market -- -- Secured over $200 million of capital to support the near-term launch of LUMRYZ -- DUBLIN, Ireland, May 04, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on tr
- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy and safety data from pivotal Phase 3 REST-ON clinical trial - - Management to host conference call today, May 1, 2023 at 4:00 p.m. ET - DUBLIN, May 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to LUMRYZ, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for t
• LUMRYZ™ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and product availability • Secured $200 million of capital to fund the launch of LUMRYZ and extended the maturity of $96.2 million of the convertible notes to 2027 • Launch preparations on track to support U.S. commercial launch of LUMRYZ • Management to host a conference call today at 8:30 a.m. ET DUBLIN, Ireland, March 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a co
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference ca
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to our board of directors," said Geoffrey M. Glass, Avadel Chairman of the Board. "Dr. Amin's extensive experience in identifying, developing, and commercializing new medicines for d
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs. "We are pleased to welcome Brandi to the Avadel team as our Senior Vice President, Corporate Affairs as we continue to advance once-at-bedtime FT218 for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy," said Greg Divis, Chief Executive Officer of Avadel. "Brandi brings a wealth of corporate affairs experience in the biopharmaceutical industry, which will support the compa
DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer. "Doug is an outstanding addition to the Avadel leadership team given his extensive experience in the biopharmaceutical industry leading R&D, clinical development and medical affairs teams in the neuroscience field," said Greg Divis, Chief Executive Officer of Avadel. "His expertise in pre- and post-approval clinical development, data generation and regulatory strategy will support all aspects of FT218 as we look to bring this important treatment t
DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of Dr. Jennifer Gudeman to the newly formed role of Vice President, Medical and Clinical Affairs, effective immediately. In this role her responsibilities will include overseeing all medical and clinical affairs activities, including the company’s lead program, once-nightly FT218. “We are pleased to further strengthen our team with the appointment of Dr. Gudeman. Her broad med
Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Oppenheimer reiterated coverage of Avadel Pharmaceuticals with a rating of Outperform and set a new price target of $29.00 from $27.00 previously
H.C. Wainwright reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $21.00 previously
Needham reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $20.00 previously
UBS initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $21.00
Jefferies upgraded Avadel Pharmaceuticals from Hold to Buy and set a new price target of $11.00 from $6.50 previously
Jefferies downgraded Avadel Pharmaceuticals from Buy to Hold and set a new price target of $8.00 from $6.00 previously
Craig Hallum resumed coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $12.00 from $15.50 previously
Stifel downgraded Avadel Pharmaceuticals from Buy to Hold and set a new price target of $2.00 from $9.00 previously
Needham reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $15.00 from $16.00 previously